Law Offices of Thomas J. Lamb

  • Asbestos & Mesothelioma
  • Benzene Diseases
  • Camp Lejeune Cases
  • Drug Injury
  • Free Case Evaluation
  • About Us

Lower Limb Amputations From All SGLT2 Inhibitors, or Just Invokana?

January 9, 2019 By Law Offices of Thomas J. Lamb, P.A.

A “Black-Box Warning” about the increased risk of lower limb amputations was added to the drug labels for Invokana and Invokamet in July 2017. Since that time there has been a mix of opinions expressed in the medical literature about whether or not lower limb amputations are a side effect of all diabetes medicines in the sodium-glucose … [Read more...]

Filed Under: Unsafe Drugs Tagged With: diabetes drugs, drug injury lawsuits, drug side effects, Farxiga, Invokamet, Invokana, Jardiance, lower limb amputations

Farxiga And Jardiance Have Two-Time Increased Risk For Amputations

November 23, 2018 By Law Offices of Thomas J. Lamb, P.A.

Patients using the diabetes drugs Farxiga and Jardiance had twice the risk for lower limb amputations relative to certain other diabetes medicines, according to a new observational study published in November 2018 by The BMJ medical journal in. However, in the US only a third diabetes drugs in the sodium-glucose cotransporter 2 (SGLT2) … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Amputations, diabetes drugs, drug injury, Farxiga, Invokamet, Invokana, Jardiance

Lower Limbs Amputations Are SGLT-2 Inhibitors Drug-Class Side Effects

October 18, 2018 By Law Offices of Thomas J. Lamb, P.A.

New medical evidence indicates that lower limbs amputations may be a “drug-class” side effect for all of the sodium-glucose cotransporter 2 (SGLT-2) inhibitor diabetes drugs which have been approved by the FDA to date. We get the following explanation of this increased risk of toe, foot, or leg amputations for Jardiance and Farxiga as well as … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Amputations, Farxiga, Glyxambi, Invokamet, Invokana, Jardiance, Leg Amputation, Toes Amputation

Invokana, Jardiance, And Farxiga Have Increased Risks Of Amputations

August 16, 2018 By Law Offices of Thomas J. Lamb, P.A.

Sodium-glucose cotransporter 2 inhibitors (SGLT-2 inhibitors) such as Invokana, Jardiance, and Farxiga have a higher risk of leg, feet, and toe amputations drug-class side effect when compared to older diabetes drugs such as sulfonylureas, metformin, and thiazolidinediones. This finding was reported in the article “Association Between … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Amputations, Farxiga, Glyxambi, Invokamet, Invokana, Jardiance, Qtern, Segluromet, Steglatro, Steglujan, Synjardy, Xigduo

Current Number Of Lawsuits Filed In The Four Diabetes Drugs Federal Court MDL Cases

February 23, 2018 By Law Offices of Thomas J. Lamb, P.A.

From the February 15, 2018 version of this document, “MDL Statistics Report – Distribution of Pending MDL Dockets by Actions Pending” (accessed 2/21/18), published by the United States Judicial Panel on Multidistrict Litigation (JPML), we get the current number of cases filed in each of the four federal court Multidistrict Litigation (MDL) cases … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Byetta, Diabetic Ketoacidosis (DKA), Farxiga, Foot Amputation, Heart Failure, Invokamet, Invokana, Janumet, Januvia, Kombiglyze, Leg Amputation, Onglyza, Pancreatic Cancer, Toes Amputation, Victoza

New SGLT2 Inhibitor Diabetes Drugs to Hit the Market in January

December 28, 2017 By Law Offices of Thomas J. Lamb, P.A.

Approval On December 19, 2017, the FDA approved Merck & Co. and Pfizer's new diabetes drug, Steglatro, and its two combination versions, Steglujan and Segluromet.  These drugs are classified as sodium/glucose cotransporter 2 (SGLT2) inhibitors, and will be available this coming January. Steglatro consists of ertugliflozin, while Steglujan … [Read more...]

Filed Under: Unsafe Drugs Tagged With: diabetes drugs side effects, drug safety news, Farxiga, Glyxambi, Invokamet, Invokana, Jardiance, merck, new sglt2 inhibitors diabetes drugs, pfizer, Qtern, Segluromet, sglt2 inhibitors diabetes drugs, Steglatro, Steglujan, Synjardy, type 2 diabetes drugs, Xigduo

Jardiance – Lower Limb Amputations Drug Safety Issue Remains Uncertain

December 4, 2017 By Law Offices of Thomas J. Lamb, P.A.

It appears there needs to more medical research done on the risk of lower limb amputations for patients who use the increasing popular diabetes medicines in the sodium glucose cotransporter 2 (SGLT2) inhibitor class, such as canagliflozin (Invokana / Invokamet), empagliflozin (Jardiance / Glyxambi / Synjardy), and dapagliflozin (Farxiga / Xigduo / … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Amputations, Farxiga, Foot Amputation, Glyxambi, Invokamet, Invokana, Jardiance, Leg Amputation, lower limb amputations, Qtern, Synjardy, Toes Amputation

SGLT2 Inhibitors May Have an Increased Risk of Acute Renal Failure

October 31, 2017 By Law Offices of Thomas J. Lamb, P.A.

SGLT2 Inhibitors: A New Side Effect In previous articles, I have discussed SGLT2 inhibitor diabetes drugs such as Invokana, Farxiga, and Jardiance and the adverse events associated with them.  Such side effects include diabetic ketoacidosis (DKA) and lower-limb amputations. A recent study identified a new possible side effect of these drugs … [Read more...]

Filed Under: Unsafe Drugs Tagged With: acute renal failure, ARF, diabetes drugs, diabetes drugs renal failure, diabetes drugs side effects, FAERS, Farxiga, FDA Adverse Event Report System Database, Glyxambi, Invokamet, invokamet xr, Invokana, Jardiance, Qtern, sglt2 inhibitors, Sodium-Glucose-Cotransporter-2 Inhibitors, Synjardy, Synjardy XR, type 2 diabetes drugs, xigduo xr

J&J Tries to Expand Invokana Label to Include Cardiovascular Benefits

October 9, 2017 By Law Offices of Thomas J. Lamb, P.A.

Johnson & Johnson's, the drug manufacturer of diabetes drugs Invokana, Invokamet, and Invokamet XR, recently submitted a supplemental new drug application (sNDA) to the FDA to request expansion of the labels for these drugs. If granted, the new label would include a cardiovascular indication concerning the reduction of risk of cardiovascular … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Cardiovascular death, diabetes drugs amputation, diabetes drugs side effects, drug label changes, FDA, foot amputations, Heart Attacks, Invokamet, invokamet xr, Invokana, johnson & johnson's, leg amputations, nonfatal myocardial infarctions, sNDA, supplemental new drug application, toe amputations, type 2 diabetes drugs

Could Invokana have been the cause of my lower-limb amputation?

September 15, 2017 By Law Offices of Thomas J. Lamb, P.A.

The FDA is investigating a connection between diabetes drugs belonging to the Sodium-Glucose Co-Transporter-2 (SGLT2) inhibitors class of drugs and the following side effects: Diabetic Ketoacidosis (DKA) Ketoacidosis Ketosis Acute Kidney Injury Kidney Failure / Renal Failure Kidney Damage Pyelonephritis (kidney infection) … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Acute Kidney Injury, amputation risk factors, blood infection, diabetes drugs, diabetic ketoacidosis, DKA, drug injury lawsuits, Farxiga, Foot Amputation, Glyxambi, Invokamet, Invokana, Jardiance, Ketoacidosis, Ketosis, Kidney Damage, Kidney Failure, kidney infection, Leg Amputation, Pyelonephritis, Qtern, Renal Failure, sglt2 inhibitors, side effects of diabetes drugs, Sodium-Glucose Co-Transporter-2 inhibitors, Synjardy, Toes Amputation, Urinary Tract Infection, Urosepsis, UTI, Xigduo

  • 1
  • 2
  • 3
  • Next Page »

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Our Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • Camp Lejeune Cases
  • GenX Water Cancer Cases
  • Drug Injury Lawsuits
  • Breast Implant Cancer Cases
  • Philips Breathing Devices Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Frequently Asked Questions
  • Disclaimer and Copyright Notices

Copyright © 2023 · Law Offices of Thomas J. Lamb, P.A.